A roundup of the latest pharma news from the United Arab Emirates (UAE) including Julpher’s pursuit of its growth strategy with a new CEO, Global Pharma’s tech transfer deal with Egypt’s Nerhado and Pharma Solutions’ procurement of its first thalassemia generic.
AstraZeneca announces move to Dubai Science Park with new sustainable offices ahead of COP28 (Emirates News Agency)
In line with this year’s focus on sustainability in the UAE, AstraZeneca has announced plans to construct sustainable offices at Dubai Science Park, a member of TECOM Group. Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global green agenda and in-line with “We the UAE 2031” vision and the Year of Sustainability.
Dubai seeks to become industrial hub in line with Dubai Industrial Strategy 2030 vision (The Economic Times)
Dubai is scaling up efforts to transform itself into a global industrial and manufacturing hub and attract major investments across key sectors such as aerospace, pharma and medical equipment, and more. This is consistent with the Dubai Industrial Strategy 2030, which projects an additional USD 5 billion in industrial sector growth by the year 2030.
In the past 10 years, the contribution of Dubai’s industrial sector to its GDP has been around 11-14 percent, making it the third largest sector, after trade and logistics. It has continued to demonstrate solid growth even during times of global crisis, buoyed by a range of strategic government initiatives and programs, such as the Dubai Industrial Strategy, to boost the global competitiveness of the sector and attract foreign investments.
Julphar appoints new CEO to drive strategic growth (Company Website)
Gulf Pharmaceutical Industries (Julphar or the Company), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced the appointment of Mr. Basel Ziyadeh as Chief Executive Officer (CEO), as the company drives its transformational growth strategy across the Middle East region and beyond.
The Company has undergone significant changes in recent years, streamlining its activities by divesting from its non-core activities and focusing on its “Strategy 2030”. The strategy aims to deliver sustainable growth around six core pillars: maximizing revenue from its current product portfolio, new product launches,geographical expansion, strategic business initiatives, advanced specialty products initiatives, and inorganic growth initiatives.
Region’s first global robotic MedTech forum to reveal latest advancements in robotic surgery (Zawya)
Dubai, United Arab Emirates: The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai. The event, the first dedicated global forum to gather world renowned experts in the region, will focus on the latest advancements in robotic surgery, a rapidly growing field that is revolutionizing healthcare.
The Forum will host ministers, senior government officials, as well as healthcare, R&D and investment professionals to discuss the future of robotic assisted surgery, in addition to the UAE’s leading position at the cutting-edge of healthcare.
Dubai Investments’ subsidiaries Global Pharma and Emirates Float Glass have entered into ‘knowledge transfer’ agreements with companies in Jordan and Egypt. This, in turn, represents an extension for Dubai Investments’ reach into new markets – and at the same time derive more from its portfolio of subsidiaries.
Global Pharma has a tech transfer deal with the Egyptian company Nerhado for production of medicines and nutritional supplements in the UAE. The company also partnered Jordanian companies Savvy Pharma and Itqan Pharma for knowledge transfer in R&D on value-added medicines. This in turn would expand the production base.
Pharma Solutions Procures The First Affordable Generic Drug For Thalassemia Patients In The UAE (Company Website)
Pharma Solutions has bought a revolution in the treatment of Thalassemia in the UAE by introducing a new drug that will cut the treatment cost by 40 percent. Manufactured in Switzerland, the medicine will be launched in the UAE by Pharma Solutions.
With the highest carrier frequency of 49 percent in the UAE, thalassemia continued to be a potential health threat to the patients. The cost of treatment was an added burden to the patients. Pharma Solutions has stepped in providing relief to the patients.
Stem cell therapies promise breakthrough in Dubai life sciences (The National News)
A new stem cell research laboratory due to open in Dubai promises to accelerate the understanding of human genomics in the region and improve health outcomes from genetic diseases.
The Hortman Stem Cell Laboratory is due to open in May on The Palm Jumeirah’s Golden Mile, with laboratories and clean rooms purpose-built for stem cell isolation, culture and expansion to take the next step in preventive health care and research in Dubai. As the UAE becomes a regional hub for life sciences, the first stem cell congress held in Dubai heard about the value of banking cord blood and placental tissue in preserving human health.